TCM
IOVA icon

Traynor Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Traynor Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,115
Closed -$249K – 228
2021
Q3 		$249K Sell
10,115
-2,010
-17% -$47.4K 0.03% 161
2021
Q2 		$320K Sell
12,125
-850
-7% -$22.1K 0.04% 133
2021
Q1 		$410K Buy
+12,975
New +$538K 0.07% 112

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Traynor Capital Management's IOVA Position: Q4 2021 in Review

Traynor Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2021, closing a stake of 10,115 shares — an estimated $249K sold.

Traynor Capital Management first reported a position in IOVA in Q1 2021 and held it in 3 quarters. The position peaked at $410K in Q1 2021. 246 funds tracked by Wall St. Rank hold IOVA as of Q4 2021.

  • Traynor Capital Management reported no remaining Iovance Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Traynor Capital Management sold 10,115 Iovance Biotherapeutics shares in Q4 2021, an estimated $249K.
  • Traynor Capital Management first reported a position in Iovance Biotherapeutics in Q1 2021 and held it in 3 quarters.
  • Traynor Capital Management's Iovance Biotherapeutics position peaked at $410K in Q1 2021.
  • 246 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2021.

Based on Traynor Capital Management's 13F filing for Q4 2021, filed 1 Feb 2022.